- Merck Q1 Non-GAAP EPS of $2.14beats by $0.31.
- Revenue of $15.9B (+49.6% Y/Y)beats by $1.26B.
- LAGEVRIO Sales Were $3.2 Billion, Growth Excluding LAGEVRIO Was 19%; Sales Growth Favorably Impacted by COVID-19 Recovery.
- 2022 Financial Outlook:
- Company Raises and Narrows Full-Year 2022 Worldwide Sales To Be Between $56.9 Billion and $58.1 Billion vs. $57.19B consensus Reflecting Projected Full-Year Growth of 17% to 19%
- Company Raises and Narrows Full-Year 2022 GAAP EPS To Be Between $5.90 and $6.02; Company Raises and Narrows Full-Year 2022 Non-GAAP EPS To Be Between $7.24 and $7.36 vs. $7.28 consensus, Including Negative Impact from Foreign Exchange of Approximately 2%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments